Insulin resistance, obesity, and liver cancer

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 1, 2014, Pages 117-119

  Farrell, Geoffrey ^a  

^a The Australian National University   (Australia)

Author keywords

HCC; HCV; NAFLD; NASH; T2D

Indexed keywords

INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; POLYPHENOL; SOMATOMEDIN C; STAT3 PROTEIN; SULFONYLUREA;

ALCOHOL CONSUMPTION; BODY MASS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SIZE; COFFEE; COLORECTAL CARCINOMA; COLORECTAL POLYP; DISEASE ASSOCIATION; DNA DAMAGE; DNA MODIFICATION; EARLY CANCER; EXERCISE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; COMPLICATION; LIVER NEOPLASMS;

HUMANS; INSULIN RESISTANCE; LIVER NEOPLASMS; OBESITY;

EID: 84890206272     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.040     Document Type: Review

References (36)

1. Wong V.W., Chu W.C., Wong G.L., et al. Prevalence of non-alcoholicfatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61:409-415.
2. Farrell G.C., Wong V.W., Chitturi S. NAFLD in Asia: as common and important as in the west. Nat Rev Gastro Hep 2013, 10:307-318.
3. Larsson S.C., Wolk A. Obesity and risk of liver cancer: meta-analysis. Br J Cancer 2007, 97:1005-1008.
4. Tanaka K., Tsuji I., Tamakoshi A., et al. Obesity and liver cancer risk: evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol 2012, 42:212-221.
5. Noto H., Osame K., Sasazuki T., et al. Substantially increased risk of cancer in patients with diabetes mellitus: systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complic 2010, 24:345-353.
6. Lai S.W., Chen P.C., Liao K.F., et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012, 107:46-52.
7. Chen C.L., Yang H.I., Yang W.S., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008, 135:111-121.
8. Ohki T., Tateishi R., Sato T., et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008, 6:459-464.
9. Veldt B.J., Chen W., Heathcote E.J., et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-1862.
10. Teoh N.C., Fan J.G. Diabetes mellitus and prognosis after curative therapy for hepatocellular carcinoma: alas, still grave for those who are hyperglycemic. J Gastroenterol Hepatol 2008, 23:1633-1634.
11. Welzel T.M., Graubard B.I., Zeuzem S., et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54:463-471.
12. Trichopoulos D., Bamia C., Lagiou P., et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011, 103:1686-1695.
13. Adams L.A., Lymp J.F., StSauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
14. Starley B., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
15. Ascha M., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
16. Bhala N., Angulo P., vanderPoorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
17. Hashimoto E., Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic?. Hepatol Res 2012, 42:1-14.
18. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol 2012, 56:1384-1391.
19. Kawamura Y., Arase Y., Ikeda K., et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012, 107:253-261.
20. Jain D., Nayak N.C., Saigal S. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients. Eur J Gastroenterol Hepatol 2012, 24:840-848.
21. White D.L., Kanwal F., El-Serag H.B. An association between non-alcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10:1342-1359.
22. Loomba R., Yang H.I., Su J., et al. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 2010, 8:891-898.
23. Cho E.J., Kwack M.S., Jang E.S., et al. Relative etiological role ofprior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011, 84(Suppl 1):17-22.
24. Arase Y., Kobayashi M., Suzuki F., et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2012, 42:264-272.
25. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev 2011, 12:1063-1070.
26. Sun B., Karin M. Obesity, inflammation, and liver cancer. JHepatol 2012, 56:704-714.
27. Park E.J., Lee J.H., Yu G.Y., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
28. Kamada Y., Matsumoto H., Tamura S., et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007, 47:556-564.
29. Saxena N.K., Fu P.P., Nagalingam A., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139:1762-1773.
30. Buitrago-Molina L.E., Vogel A. mTOR as a potential target for the prevention and treatment of hepatocellular carcinoma. Curr Cancer Drug Targets 2012, 12:1045-1061.
31. Menon S., Yecies J.L., Zhang H.H., et al. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 2012, 5:ra24.
32. Sang L.X., Chang B., Li X.H., et al. Consumption of coffee associated with reduced risk of liver cancer: a meta-analsysis. BMC Gastroenterol 2013, 13:34.
33. Bravi F., Bosetti C., Tavani A., et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013, 11:1413-1421.
34. Hassan M.M., Curley S.A., Li D., et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010, 116:1938-1946.
35. Marchesini G., Forlani G. Diabetes and hepatocellular carcinoma: not only a matter of hyperglycemia. Hepatology 2012, 55:1298-1300.
36. Wang Y., Ausman L.M., Greenberg A.S., et al. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. Int J Cancer 2010, 126:1788-1796.